Gastrointestinal Stromal Tumors Clinical Trial
Official title:
Gastrointestinal Stromal Tumors (GIST) Registry Protocol: reGISTry
The goal of this observational research study is to establish a registry of information
regarding how different physicians treat and manage patients with gastrointestinal stromal
tumors (GISTs).
Objectives:
1. To describe variation in management of patients with GIST, overall and by patient and
provider characteristics.
2. To provide participating physicians with information regarding management of their
patients with GIST compared to the aggregate experience of all physicians participating
in the Registry.
The Registry, which is Internet based, is intended to collect information about current
practices in the management of GIST without making any specific change to the standard of
care as decided by each patient's treating physician.
If you agree to participate in this study, your doctor will provide information to a data
registry about your physical and clinical traits, the past and current medical care you have
received to treat your GIST, and clinically-related, economically-related, and
health-related quality of life information. About 200 doctors will provide information on
their patients for the Registry. Your doctor will collect this information when you first
join the Registry and at each regularly scheduled visit you make to your doctor's office.
The information collection will continue for as long as you and your doctor feel it is
appropriate. The information that is entered into the Registry will remain there
indefinitely. It is hoped that this sharing of information will lead to a better
understanding of how to best treat patients with GIST.
You and your doctor will decide what treatment you will receive. Because this Registry is
only to observe actual medical practice, it does not require you to receive any particular
treatment.
Only your doctor and people who will help your doctor collect the information for this
Registry will know which information submitted to the Registry belongs to you. Data will be
tracked in the Registry using only ID numbers and patient initials. The information
submitted on the Registry data collection forms will not be associated with a specific
patient's identity. Separately, you will be asked to provide your name, place of birth, and
Social Security number. This information will not be entered into the Registry databases and
will only be used if it is necessary to perform a search should you become lost to follow
up. If you do not want to provide your Social Security number you may still be enrolled in
the Registry.
This is an investigational study. About 100 patients from M. D. Anderson will be entered
into the Registry. In all, about 1800 patients will be registered. The Registry will be
active for at least 7 years.
;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05385549 -
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
|
Phase 2 | |
Recruiting |
NCT05905887 -
Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal Tumor
|
Phase 2 | |
Completed |
NCT01933958 -
Regorafenib Post-marketing Surveillance in Japan
|
||
Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
Completed |
NCT01440959 -
Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258
|
Phase 2 | |
Completed |
NCT00718562 -
Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib
|
Phase 2 | |
Completed |
NCT00385203 -
The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
|
Phase 2 | |
Completed |
NCT00137449 -
Study Of SU011248 Administered On A Continuous Daily Dosing Schedule In Patients With Gastrointestinal Stromal Tumor
|
Phase 2 | |
Completed |
NCT00237172 -
Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
|
Phase 2 | |
Terminated |
NCT04409223 -
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
|
Phase 3 | |
Active, not recruiting |
NCT03556384 -
Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
|
Phase 2 | |
Recruiting |
NCT04106024 -
Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial
|
Phase 2 | |
Completed |
NCT02171286 -
The Oncopanel Pilot (TOP) Study
|
N/A | |
Completed |
NCT01114087 -
Impact of the Inhibitors of Tyrosine Kinase on the Male Fertility
|
N/A | |
Recruiting |
NCT05366816 -
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
|
Phase 2 | |
Recruiting |
NCT03602092 -
Observational Registry Data on GIST Patients
|
||
Recruiting |
NCT05197933 -
Safety of Laparoscopic Resection for Gastrointestinal Stromal Tumor on Unfavorable Anatomic Site of Stomach
|
N/A | |
Completed |
NCT02931929 -
MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05080621 -
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
|
Phase 1/Phase 2 | |
Completed |
NCT02607332 -
Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib
|
Phase 2 |